Shares of The Green Organic Dutchman Holdings (TGOD) (TSX:TGOD,OTCQX:TGODF) were crushed at the open of Tuesday’s (November 26) market after the cannabis producer announced a change in its much-needed financing plans.

TGOD informed shareholders on Tuesday it would no longer conduct a previously announced finance through a series of actions; instead, it will pursue a new agreement with Canaccord Genuity.

According to the producer, the new deal will lead it to raise approximately C$22 million in gross proceeds, as part of an offering of 29.3 million shares at a price of C$0.75 per share.

TGOD faced a drop of nearly 16 percent near the end of the trading session on Tuesday, resulting in a price per share of C$0.74 after closing at C$0.89 the previous day.

stock chart for TGOD

The company will offer its shares by way of a short form prospectus deal, which is expected to close on December 17.

According to TGOD, this deal offers the company more capital at the closing of the transaction and is “less dilutive” compared to its previously revealed financing plan.

“TGOD intends to use the proceeds of the offering to complete construction of its processing facility at Ancaster and for general corporate purposes,” the company said.

On November 14, the company had championed the arrival of a C$103 million funding deal, split into separate phases of activation for the total amount.

Brian Athaide, CEO of TGOD, had said the previously announced financing deal was a show of confidence for the company; however, now TGOD has elected to go forward with the deal from the boutique financial institution.

All the funding being pursued by TGOD is in the hopes to complete the construction of its processing facility in Ancaster, Ontario, and a separate operation in Quebec.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and ATB Capital Markets, under which the underwriters have agreed to buy on bought deal basis 12,000,000 units of the Company (the “Units”), at a price of US$10.45 per Unit for gross proceeds of approximately US$125 million (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less


Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less